Sun, Yihan
Kim, Jae Hyun
Vangipuram, Kiran
Hayes, Daniel F.
Smith, Ellen M. L.
Yeomans, Larisa
Henry, N. Lynn
Stringer, Kathleen A.
Hertz, Daniel L. http://orcid.org/0000-0003-0501-1035
Funding for this research was provided by:
Michigan Institute for Clinical and Health Research (5KL2RR024987)
National Institute of General Medical Sciences (NIGMS R01 GM111400)
Article History
Received: 15 June 2018
Accepted: 20 June 2018
First Online: 26 June 2018
Compliance with ethical standards
:
: Dr. Daniel F. Hayes reports financial interest with Oncimmune LLC and Inbiomotion, serves as a consultant for Cepheid (no compensation), receives research grants from Merrimack Pharmaceuticals, Inc, Eli Lilly Company, Menarini/Silicon BioSystems, Puma Biotechnology, Inc, Pfizer, and Astra Zeneca, receives royalties from licensed technology from Janssen R&D, LLC, and holds three patents. The rest of the authors declare no conflict of interest.
: The study was approved by the University of Michigan IRBMed (HUM 00086253). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.